QLT gets EU blow for Visudyne therapy
This article was originally published in Clinica
Executive Summary
QLT received a blow last week as the European Medicines Agency's (EMEA) Committee for Medicinal Products (CHMP) recommended to the European Commission (EC) that the indication for the use of its Visudyne product in the treatment of occult subfoveal choroidal neovascularisation (CNV), secondary to age-related macular degeneration (AMD), be deleted. The information was posted on the EMEA website on Friday April 27.